Across TCGA pan-cancer cohorts, IGHV3-53 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated IGHV3-53 data layer compared with 28 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher IGHV3-53 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated IGHV3-53 expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

LIHC, SKCM, and TGCT are the cancer types where IGHV3-53 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	DFS	Median	All	0.040	0.553	<.001	18	view →
SKCM	DFS	Median	II,III,IV	1.000	0.558	.012	9	view →
TGCT	DFS	Median	All	0.151	0.801	.026	6	view →
LUAD	DFS	Median	All	0.444	0.770	.025	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: IGHV3-53 tumor-vs-normal RNA expression · all IGHV3-53 data types